These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 19846841)
41. FDA Modernization Act: implications for oncology. Morris L Oncology (Williston Park); 1998 Nov; 12(11A):139-41. PubMed ID: 10028506 [TBL] [Abstract][Full Text] [Related]
42. From the Food and Drug Administration. Henney JE JAMA; 1999 Oct; 282(13):1218. PubMed ID: 10517411 [No Abstract] [Full Text] [Related]
43. Update on hypnotics for insomnia in clinical practice: I. Hypnotics. DiBella GA Mt Sinai J Med; 1986 Feb; 53(2):82-9. PubMed ID: 3486358 [No Abstract] [Full Text] [Related]
44. FDA prohibits extralabel use of two drug classes. J Am Vet Med Assoc; 1997 Aug; 211(3):269. PubMed ID: 9262656 [No Abstract] [Full Text] [Related]
45. Stoning a dead bird: advertising limits on approved new drugs. Strobos J Food Drug Law J; 1995; 50(4):533-51. PubMed ID: 10343018 [No Abstract] [Full Text] [Related]
46. Treatment of insomnia. Treat Guidel Med Lett; 2006 Feb; 4(42):5-10. PubMed ID: 16467736 [No Abstract] [Full Text] [Related]
47. Deterring inefficient pharmaceutical litigation: an economic rationale for the FDA regulatory compliance defense. Viscusi WK; Rowland SR; Dorfman HL; Walsh CJ Spec Law Dig Health Care Law; 1996 Mar; (205):9-52. PubMed ID: 10156421 [No Abstract] [Full Text] [Related]
48. Drugs for insomnia. Treat Guidel Med Lett; 2009 Mar; 7(79):23-6. PubMed ID: 19229159 [No Abstract] [Full Text] [Related]
49. Labeling of diphenhydramine-containing drug products for over-the-counter human use. Final rule. Food and Drug Administration, HHS Fed Regist; 2002 Dec; 67(235):72555-9. PubMed ID: 12474879 [TBL] [Abstract][Full Text] [Related]
50. FDA perspectives on supplement use by patients on antithrombotic therapy: dietary supplement regulatory overview. Woo JJ Thromb Res; 2005; 117(1-2):193-6; discussion 201-7. PubMed ID: 16253311 [No Abstract] [Full Text] [Related]
51. Suvorexant for the treatment of insomnia. Jacobson LH; Callander GE; Hoyer D Expert Rev Clin Pharmacol; 2014 Nov; 7(6):711-30. PubMed ID: 25318834 [TBL] [Abstract][Full Text] [Related]
52. [Sleep disorders--diagnosis and treatment. Recommendations of the German Society of Sleep Research and Sleep Medicine]. Bornkessel B Med Monatsschr Pharm; 1996 Apr; 19(4):106-9. PubMed ID: 8684302 [No Abstract] [Full Text] [Related]
53. [Care and treatment of insomnia]. Syvälahti E Duodecim; 2005; 121(18):1950-1. PubMed ID: 16300308 [No Abstract] [Full Text] [Related]
54. Hypnotic -- treatment or toxin? Waring S; Vendur K J Am Assoc Nephrol Nurses Tech; 1976; 3(1):25-8. PubMed ID: 1048140 [No Abstract] [Full Text] [Related]
55. Tricky FDA debate: should a risky drug be approved again? Mathews AW; Westphal SP Wall St J (East Ed); 2006 Feb; ():B1, B4. PubMed ID: 16528879 [No Abstract] [Full Text] [Related]
56. Psychotropic drug advertisements. Ditzion BR Ann Intern Med; 1971 Sep; 75(3):473-4. PubMed ID: 5568161 [No Abstract] [Full Text] [Related]
57. Quaalude and insomnia. Med Lett Drugs Ther; 1966 Apr; 8(8):29-30. PubMed ID: 5913762 [No Abstract] [Full Text] [Related]
58. [Observations on use of modern hypnotics. More rapid sleep onset, more frequent uninterrupted sleep and sleep duration]. Wiegand MH; Roszinsky-Köcher G; Schwalb B; Fischer W; Eckert MW MMW Fortschr Med; 2001 Feb; 143(8):42. PubMed ID: 11265539 [No Abstract] [Full Text] [Related]
59. Consumer-directed advertising of contraceptive drugs: the FDA, Depo-Provera, and product liability. Green W Food Drug Law J; 1995; 50(4):553-67. PubMed ID: 10343019 [No Abstract] [Full Text] [Related]
60. Sleeping pills: when are they a safe answer for those who can't sleep? Gillin JC AAOHN J; 1987 Apr; 35(4):184-6. PubMed ID: 2950891 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]